Financial Times FT.com

Medarex's Phase III melanoma drug Ipilimumab likely to be rejected by FDA due to missed primary endpoint, physicians say

By Klara Czobor in New York

Published: February 1 2008 15:54 | Last updated: February 1 2008 15:54

Copyright The Financial Times Limited 2009. You may share using our article tools. Please don't cut articles from FT.com and redistribute by email or post to the web.

Email options

The information entered on this page will not be used to send unsolicited email, and will not be sold to a 3rd party.Terms of use |Privacy policy

* required fields



(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)





"FT" and "Financial Times" are trademarks of The Financial Times.Privacy policy | Terms
© Copyright The Financial Times Ltd 2009